Skip to main
BLTE

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc has demonstrated notable progress in its clinical trials, with the DRAGON trial showing a statistically significant 36% reduction in atrophic lesion growth in Stargardt disease, indicating potential for product approval in a market with unmet medical needs. Additionally, the company's recent equity financing has resulted in a revised market value of approximately $3.42 billion, reflecting investor confidence and interest in its long-term prospects. With ongoing developments in other therapeutics for conditions such as non-alcoholic fatty liver disease and type 2 diabetes, Belite Bio is well-positioned to capitalize on increasing demand for innovative treatments targeting retinal and metabolic diseases.

Bears say

The financial outlook for Belite Bio Inc reflects significant concerns regarding the commercialization potential of its lead candidate, tinlarebant, primarily due to the substantial price reductions required for broader indications beyond its initial orphan market. The company's projected capital expenditures, with cumulative R&D spending anticipated to reach approximately $2.7 billion in 2027 and beyond, indicate challenges in supporting the forecasted $3.1 billion revenue following the expiration of tinlarebant's patent in 2040. Additionally, the ongoing risks related to clinical trial outcomes, regulatory approvals, and market competition further contribute to a low confidence in the successful transition from Phase 3 studies to meaningful commercial success.

BLTE has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 6 analysts, BLTE has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.